Elanco Animal Health Stock Today
| ELAN Stock | USD 13.13 0.26 1.94% |
Performance0 of 100
| Odds Of DistressLess than 42
|
Elanco Animal is selling at 13.13 as of the 28th of November 2024; that is 1.94 percent decrease since the beginning of the trading day. The stock's open price was 13.39. Elanco Animal has about a 42 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Note, on July 8, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Elanco Animal Health's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of September 2018 | Category Healthcare | Classification Health Care |
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana. Elanco Animal operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. The company has 494.35 M outstanding shares of which 15.16 M shares are currently shorted by private and institutional investors with about 3.2 trading days to cover. More on Elanco Animal Health
Moving together with Elanco Stock
| 0.7 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.63 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Elanco Stock
Elanco Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Jeffrey Simmons | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, Pharmaceutical Products, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsElanco Animal can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Elanco Animal's financial leverage. It provides some insight into what part of Elanco Animal's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Elanco Animal Health (ELAN) is traded on New York Stock Exchange in USA. It is located in 2500 Innovation Way, Greenfield, IN, United States, 46140 and employs 9,300 people. Elanco Animal is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.49 B. Elanco Animal Health conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 494.35 M outstanding shares of which 15.16 M shares are currently shorted by private and institutional investors with about 3.2 trading days to cover.
Elanco Animal Health currently holds about 463 M in cash with 271 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.98.
Check Elanco Animal Probability Of Bankruptcy
Ownership AllocationElanco Animal holds a total of 494.35 Million outstanding shares. The majority of Elanco Animal Health outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Elanco Animal Health to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Elanco Animal. Please pay attention to any change in the institutional holdings of Elanco Animal Health as this could imply that something significant has changed or is about to change at the company. On July 8, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Elanco Animal Health's common stock.
Check Elanco Ownership Details
Elanco Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-06-30 | 9.7 M | |
| Millennium Management Llc | 2024-06-30 | 9.4 M | |
| Geode Capital Management, Llc | 2024-09-30 | 7.9 M | |
| Citadel Advisors Llc | 2024-09-30 | 7.5 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 6.9 M | |
| Manufacturers Life Insurance Co | 2024-09-30 | 6.4 M | |
| Jpmorgan Chase & Co | 2024-06-30 | 5.7 M | |
| Balyasny Asset Management Llc | 2024-09-30 | 4.7 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 4.5 M | |
| Dodge & Cox | 2024-09-30 | 83.3 M | |
| Primecap Management Company | 2024-09-30 | 52.6 M |
Elanco Animal Historical Income Statement
Elanco Stock Against Markets
Elanco Animal Corporate Directors
| Joshua Smiley | Independent Director | Profile | |
| Carl McMillian | Independent Director | Profile | |
| Denise ScotsKnight | Independent Director | Profile | |
| Kirk McDonald | Independent Director | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elanco Animal Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Elanco Animal. If investors know Elanco will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Elanco Animal listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.71) | Earnings Share 0.41 | Revenue Per Share 9.023 | Quarterly Revenue Growth (0.04) | Return On Assets 0.0118 |
The market value of Elanco Animal Health is measured differently than its book value, which is the value of Elanco that is recorded on the company's balance sheet. Investors also form their own opinion of Elanco Animal's value that differs from its market value or its book value, called intrinsic value, which is Elanco Animal's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Elanco Animal's market value can be influenced by many factors that don't directly affect Elanco Animal's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Elanco Animal's value and its price as these two are different measures arrived at by different means. Investors typically determine if Elanco Animal is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Elanco Animal's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.